Allovir Inc expected to post a loss of 53 cents a share - Earnings Preview

Kalaris Therapeutics

01/11/2022 15:13

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on November 3
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Allovir Inc is for
a loss
of 53 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$26​, above​ its last closing price of $6.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.73       -0.73      -0.69     Beat    5.5
 Mar. 31 2022  -0.80       -0.80      -0.69     Beat    13.4
 Dec. 31 2021  -0.78       -0.81      -0.92     Missed  -13.1​
 Sep. 30 2021  -0.58       -0.55      -0.72     Missed  -30.9
 ​​Jun.        -0.54       -0.49      -0.60     Missed  -22.4
 30 2021                                                
 Mar. 31 2021  -0.40       -0.40      -0.50     Missed  -24.2​
 Dec. 31 2020  -0.42       -0.42      -0.34     Beat    19
 Sep. 30 2020  -0.30       -0.30      -0.58     Missed  -93.3
 This summary was machine generated November 1 at 15:13 GMT.  All
figures in US dollars  unless otherwise stated